ARTICLE | Company News
Elan, Spectral Diagnostics deal
July 21, 2003 7:00 AM UTC
The companies ended their 1998 deal to develop and commercialize sepsis assays including SDI's Endotoxin Activity Assay (EAA), which is marketed to identify patients at risk for developing severe sep...